Title: Anti-inflammatory Therapeutics Market 2020
1Anti-inflammatory Therapeutics Asia-Pacific
Market Research Report, 2014-2020
(Type, Mode of action, Crop Type and Geography) -
Size, Share, Global Trends, Company Profiles,
Demand, Insights, Analysis, Research, Report,
Opportunities, Segmentation and Forecast, 2013 -
2020
TELEPHONE 1 (855) 711-1555E-MAIL
sales_at_researchbeam.com
Published on Oct 2014
2 Report Overview
The Asia-Pacific anti-inflammatory therapeutics
market is expected to grow at a CAGR of 8.6 over
the forecast period, owing to the rising
healthcare expenditure, disposable income of
individuals, increasing popularity of biologics
and better healthcare access. Increase in the
number of autoimmune and respiratory diseases,
new drugs in development pipeline and increased
usage of OTC NSAIDs are the major factors driving
the Asia-Pacific anti-inflammatory market.
Moreover, increasing awareness of
anti-inflammatory biologics and favorable
government initiatives in the Asia-Pacific region
are expected to drive the market during the
analysis period. Factors, such as side effects of
anti-inflammatory drugs and uncertain patent
legislations, i.e., compulsory licensing in India
would continue to impede the market growth. The
Asia-Pacific anti-inflammatory therapeutics
market is segmented on the basis of indication,
drug class and geography. The indications
considered in this report include arthritis,
respiratory diseases, multiple sclerosis,
psoriasis, inflammatory bowel disease and other
inflammatory diseases. Among indications,
arthritis was the dominant segment accounting for
41.3 of the APAC anti-inflammatory therapeutics
market in 2014 and holds potential for growth
during the forecast period. Anti-inflammatory
biologics are the most preferred drugs for
treatment of arthritis. Read Complete Report _at_
http//www.researchbeam.com/anti-inflammatory-ther
apeutics-market
3 Report Overview
On the basis of drug class, the market is
segmented into anti-inflammatory biologics,
non-steroidal anti-inflammatory drugs (NSAIDs)
and corticosteroids. Anti-inflammatory biologics
holds the largest share among drug classes
accounting for around 50 share of the
Asia-Pacific anti-inflammatory therapeutics
market, and is expected to grow rapidly during
the forecast period. Geographically, the market
is segmented into six countries namely Japan,
China, India, Australia, South Korea, Indonesia
and others. Among these countries, Japan holds
the largest share in the Asia-Pacific
anti-inflammatory therapeutics market however,
China is expected to exhibit the fastest growth
during the forecast period. Major market players
have adopted strategies such as collaborations,
indication expansions and product launches to
expand their market presence. In 2014, Novartis
got marketing approval for the drug Cosentyx
(secukinumab) in Japan for the treatment of
psoriatic arthritis. The company has filed new
patents to overcome the issues of patent expiries
of their existing drugs and to gain a prominent
market share. The key companies profiled in this
report are Pfizer, Inc., AbbVie, Inc., Johnson
Johnson, GlaxoSmithKline plc, Merck CO., Inc.,
Novartis AG, F. Hoffmann-La Roche AG, Eli Lily
and Company, AstraZeneca PLC and Amgen. Enquire
_at_ http//www.researchbeam.com/anti-inflammatory-t
herapeutics-market/enquire-about-report
4 Report Overview
- KEY MARKET BENEFITS
- The report provides a quantitative analysis of
the current market and estimations during
20142020 that assist in identifying and
capitalizing on the prevailing market
opportunities - Exhaustive analysis of the Asia-Pacific
anti-inflammatory therapeutics market by product
type helps in understanding the types of
therapeutics and their categories that are
currently being used to gain prominence in future - Competitive intelligence of leading manufacturers
and distributors of anti-inflammatory
therapeutics helps in understanding the
competitive scenario across the geographies - Comprehensive analysis of factors that drive and
restrict the growth of the Asia-Pacific
anti-inflammatory therapeutics market has been
provided - SWOT analysis facilitates the study of internal
environment of leading companies for strategic
decision-making - The country-wise analyses of anti-inflammatory
therapeutics market conditions have been provided
in this report
5 Report Overview
- KEY MARKET SEGMENTS
- The Asia-Pacific Anti-inflammatory Therapeutics
Market is segmented below - Asia-Pacific Anti-inflammatory Therapeutics
Market - By Indication - Arthritis
- Respiratory diseases
- Multiple sclerosis
- Psoriasis
- Inflammatory bowel disease
- Other inflammatory diseases
- Asia-Pacific Anti-inflammatory Therapeutics
Market - By Drug Class - Anti-Inflammatory Biologics
- Non-Steroidal Anti-inflammatory drugs (NSAIDs)
- Corticosteroids
6 Report Overview
- Asia-Pacific Anti-inflammatory Therapeutics
Market - By Country - Japan
- China
- India
- Australia
- South Korea
- Indonesia
- Other APAC countries
7 Table of Contents
- CHAPTER 1 INTRODUCTION
- CHAPTER 2 EXECUTIVE SUMMARY
- CHAPTER 3 MARKET OVERVIEW
- CHAPTER 4 ASIA-PACIFIC ANTI-INFLAMMATORY
THERAPEUTICS MARKET BY INDICATION - CHAPTER 5 ASIA-PACIFIC ANTI-INFLAMMATORY
THERAPEUTICS MARKET BY DRUG CLASS - CHAPTER 6 ASIA-PACIFIC ANTI-INFLAMMATORY
THERAPEUTICS MARKET BY COUNTRY
8 FOR MORE DETAILS
Visit us at
http//www.researchbeam.com
Stay With Us
5933 NE Win Sivers Drive,205, Portland, OR
97220United States
TELEPHONE 1 (855) 711-1555E-MAIL
sales_at_researchbeam.com